title: Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia.
abstract: OBJECTIVE
  Methotrexate (MTX) resistance is defined on the basis of the human chorionic gonadotropin (hCG) curve. The aim of this study was to identify low-risk non-metastatic patients with gestational trophoblastic neoplasia (GTN) who can achieve resolution by continuing MTX treatment despite a transient hCG plateau.
  
  
  METHODS
  Before starting chemotherapy, 24 patients with FIGO Stage I GTN underwent transvaginal ultrasonography with power Doppler in order to identify myometrial lesions (areas of increased echogenicity and increased power Doppler signal). Ultrasound response to chemotherapy was defined when myometrial lesions decreased in echogenicity, Doppler signal or size. When ultrasound response occurred, despite chemoresistance defined by hCG values, MTX treatment was continued.
  
  
  RESULTS
  MTX was continued in three out of seven chemoresistant patients because ultrasound suggested response to MTX. All three of these patients achieved a complete response, thus nearly halving the MTX-resistance rate.
  
  
  CONCLUSIONS
  Among patients who are candidates for second-line treatment on the basis of hCG, ultrasound may identify those in whom further MTX administration can induce a delayed complete response.
authors.affiliation: IRCCS San Raffaele Hospital, Obstetrics and Gynecology Department, Vita-Salute University, Milan, Italy. cavoretto.paolo@hsr.it
authors.forename: P
authors.initials: P
authors.lastname: Cavoretto
authors.forename: C
authors.initials: C
authors.lastname: Gentile
authors.forename: G
authors.initials: G
authors.lastname: Mangili
authors.forename: E
authors.initials: E
authors.lastname: Garavaglia
authors.forename: L
authors.initials: L
authors.lastname: Valsecchi
authors.forename: D
authors.initials: D
authors.lastname: Spagnolo
authors.forename: S
authors.initials: S
authors.lastname: Montoli
authors.forename: M
authors.initials: M
authors.lastname: Candiani
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011247:Pregnancy; D012307:Risk Factors; D014463:Ultrasonography / Q000379:methods; D014621:Vagina; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate